Figure 2.

Percentage of patients developing ≥1 adverse event or remaining seizure-free within daily average phenytoin concentration intervals. A) Total phenytoin; B) Free phenytoin.

Percentage of patients developing ≥1 adverse event or remaining seizure-free within daily average phenytoin concentration intervals. A) Total phenytoin; B) Free phenytoin.